0001299933-13-001952.txt : 20131105 0001299933-13-001952.hdr.sgml : 20131105 20131105161555 ACCESSION NUMBER: 0001299933-13-001952 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20131105 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20131105 DATE AS OF CHANGE: 20131105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOPHIRIS BIO INC. CENTRAL INDEX KEY: 0001563855 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36054 FILM NUMBER: 131192790 BUSINESS ADDRESS: STREET 1: 1258 PROSPECT STREET CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-777-1760 MAIL ADDRESS: STREET 1: 1258 PROSPECT STREET CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 htm_48773.htm LIVE FILING Sophiris Bio Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   November 5, 2013

Sophiris Bio Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
British Columbia 001-36054 98-1008712
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
1258 Prospect Street, La Jolla, California   92037
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   858-777-1760

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

(d) On November 5, 2013, Sophiris Bio Inc. (the "Company") announced that it had applied to the Toronto Stock Exchange (the "TSX") to voluntarily delist from trading its shares of common stock. The TSX has indicated that effective at market close on November 13, 2013, the Company’s common stock will no longer be traded through the facilities of the TSX. The Company’s shares are currently traded, and will continue to be traded, on the NASDAQ Global Market under the symbol "SPHS".





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Sophiris Bio Inc.
          
November 5, 2013   By:   /s/ Peter T. Slover
       
        Name: Peter T. Slover
        Title: Chief Financial Officer

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press Release dated November 5, 2013.
EX-99.1 2 exhibit1.htm EX-99.1 EX-99.1


FOR IMMEDIATE RELEASE

Sophiris Bio Applies for Voluntary Delisting from TSX

San Diego, California and Vancouver, British Columbia, November 5, 2013 – Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has applied for voluntary delisting of its common shares from the Toronto Stock Exchange (“TSX”). Sophiris’ common shares are currently listed for trading on the NASDAQ Global Market and the TSX. After delisting from the TSX, the Company’s shares will continue to trade on NASDAQ under the symbol “SPHS”.

After careful consideration, the Directors of the Company decided to delist from the TSX due to the minimal trading activity of the Company’s common shares on the TSX which no longer justifies the expense and administrative efforts associated with maintaining a dual listing and that the Company’s NASDAQ listing and trading volume will provide Sophiris shareholders with sufficient liquidity.

“Delisting from the TSX creates a central marketplace on NASDAQ for Sophiris shares,” explained Randall Woods, President and CEO of Sophiris. “With Sophiris operations based in the United States, strong exposure to the U.S. financial community, and a Phase 3 trial now underway for PRX302, we believe this was a prudent move for shareholders.”

Subject to the application being accepted by the TSX, the Company expects the delisting to be effective on or about November 13, 2013.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris initiated its first Phase 3 clinical trial of PRX302 in October 2013. For more information, please visit www.sophiris.com.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking, including the expectation that the Company’s shares will be delisted from the TSX and that shareholders will have sufficient liquidity. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, the delisting of the common shares from the TSX, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Peter Slover
Chief Financial Officer
(858) 777-1760

     
Corporate Communications and Investor Relations:
 
Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com
  Michael Moore
Equicom Group
619-467-7067
mmoore@tmxequicom.com

GRAPHIC 3 e39036-13309143859770f98c_1.jpg GRAPHIC begin 644 e39036-13309143859770f98c_1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``5`!@#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^R_\`:,_; M:^$O[/5P^@:EJ>FZSX[AU#0[.7P9=ZC>>&YV3Q%;L^DFUUV]T6[T*YOKZYET MZVM=+6\%W/\`;3(HW6[Q-S\_[8'A77[;P7\1/"^LVMO\+WL7U3Q7<:O!-:7^ MB1V=[J-AXP@UFWMTO9)+SP?9VK7P@T::\L;XQS:I87>N:.VF:@?F3_@K_P#L M<>,OVD?@-K_B3X6Z3>^)/&OAWPZ;/6_!UC-J5QJGBKPKI5^WB.R_X1?2;>/4 M/MFOZ%K*/=W6@Z!86?B/QQH%[J6E6%SK7B/2/!/AR\_B0U/]O7]H3X4?L\?' MG]DWXB^'?B-%\6+;XT>`?"=DVN?#^WN9?#T/AFP^(DOC0^,M:UU6/7K+X86=11JX>C4<(4\!7JTZOCK-,7@,QQ M4<5@X8C!2P.,^J.,96^M1H^TPSG-\W+S3C+#U4KN$Y4Z].,8W4O]`#X(_P#! M0WX#_&OQ5/X3L=6B\.:K>ZMH.C^$M&U&ZDU3Q3K=WKEJES$FLZ)H%EJ5KX0( M%S8_9FU36);:^CN)9XKE(K29J*_+W_@B'^P)\6_A1X.'QC_:2\+ZCX;\0ZGJ MFM:MI'@[QS;7[^.9_%YO;.TD\;>(5U'[%J-A;V2:7.=+T_7[;5I]<\3WM]XZ MT^:ST[3_``=KGB$K]CX*Q/%.,RJIB.)UAX5YXNM]1Y,,Z&(J8'F4H5<32C.% M.DW*52EAZ:IQJ/#4J-:M.I4K2D;Y55QM;"JIF$%3JRDW&*@X2Y-+2G%M\M]5 M"*2M!1E*4W)R/W^^(5EXFU+PU=:?X.\1VOA+Q'?/]FT[Q#>Z+)XCM=+=X)S- M=/H<>L:"-1FCMUE:PCGU..T@U$6=W>VVIV=O/I=[S'C+2/&7BKPWXC\-^"O' M-(]"LO%JZ?!:WUI=:G'+X